Romiplostim
Phase 2/3Completed 0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Aplastic Anemia
Conditions
Aplastic Anemia
Trial Timeline
Apr 25, 2019 → May 26, 2021
NCT ID
NCT03957694About Romiplostim
Romiplostim is a phase 2/3 stage product being developed by Kyowa Kirin for Aplastic Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03957694. Target conditions include Aplastic Anemia.
What happened to similar drugs?
1 of 7 similar drugs in Aplastic Anemia were approved
Approved (1) Terminated (2) Active (5)
Hype Score Breakdown
Clinical
15
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04095936 | Phase 2/3 | Completed |
| NCT03957694 | Phase 2/3 | Completed |
| NCT02773290 | Phase 2/3 | Completed |
| NCT02868060 | Phase 1/2 | Completed |
Competing Products
20 competing products in Aplastic Anemia